Trevi Therapeutics, Inc. (NASDAQ:TRVI) Stock Rated “Buy” by Sell-Side Analysts

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have been assigned a consensus rating of “Buy” from the thirteen ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, ten have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $27.08.

Several analysts have issued reports on the stock. Cantor Fitzgerald boosted their target price on shares of Trevi Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. BMO Capital Markets started coverage on Trevi Therapeutics in a research report on Monday, July 20th. They issued an “outperform” rating and a $36.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Friday, July 17th. HC Wainwright upped their price target on Trevi Therapeutics from $21.00 to $24.00 and gave the company a “buy” rating in a research report on Monday, July 20th. Finally, Raymond James Financial reissued a “strong-buy” rating and issued a $40.00 price objective on shares of Trevi Therapeutics in a research note on Friday, August 7th.

Insider Buying and Selling at Trevi Therapeutics

In other news, Director Michael Heffernan sold 39,473 shares of the company’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $15.09, for a total value of $595,647.57. Following the transaction, the director owned 6,351 shares in the company, valued at $95,836.59. This represents a 86.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 15.39% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. KBC Group NV acquired a new position in shares of Trevi Therapeutics in the first quarter worth $29,000. Hilton Head Capital Partners LLC purchased a new stake in shares of Trevi Therapeutics during the fourth quarter worth $40,000. Caitong International Asset Management Co. Ltd acquired a new stake in Trevi Therapeutics during the fourth quarter valued at $50,000. Avidity Partners Management LP acquired a new stake in Trevi Therapeutics during the first quarter valued at $79,000. Finally, Seven Fleet Capital Management LP acquired a new stake in Trevi Therapeutics during the fourth quarter valued at $89,000. 95.76% of the stock is owned by hedge funds and other institutional investors.

Trevi Therapeutics Trading Down 1.8%

Shares of TRVI opened at $14.41 on Friday. The business’s 50-day moving average price is $17.17 and its 200 day moving average price is $15.39. The stock has a market capitalization of $2.05 billion, a P/E ratio of -42.38 and a beta of 1.04. Trevi Therapeutics has a 1-year low of $8.24 and a 1-year high of $20.22.

Trevi Therapeutics (NASDAQ:TRVI) last announced its earnings results on Thursday, August 6th. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). On average, research analysts predict that Trevi Therapeutics will post -0.48 earnings per share for the current year.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for chronic cough and other conditions involving dysregulated sensory nerve activity. The company’s lead product candidate is Haduvio, an oral extended-release formulation of nalbuphine designed to reduce chronic cough through activity at opioid receptors.

Trevi is studying Haduvio for chronic cough associated with idiopathic pulmonary fibrosis, a progressive lung disease, as well as refractory chronic cough, a condition in which coughing persists despite treatment of underlying causes.